Prime Medicine, Inc. develops genetic medicines using its proprietary Prime Editing platform, which is designed to make targeted edits within genes. News about PRME centers on its pipeline for genetically defined diseases, including PM577 for Wilson Disease, PM647 for Alpha-1 Antitrypsin Deficiency and PM359, an investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease.
Company updates also cover financial results, regulatory interactions, clinical-data publications, investor conference participation and finance leadership changes. Additional recurring themes include an in vivo cystic fibrosis program supported by the Cystic Fibrosis Foundation and Prime Edited CAR-T product development with Bristol Myers Squibb for hematology, immunology and oncology.
Prime Medicine, Inc. (Nasdaq: PRME) has successfully completed its upsized initial public offering, issuing 10,294,118 shares at $17.00 each, raising approximately $175 million before expenses. The underwriters also hold a 30-day option to purchase an additional 1,544,117 shares. Shares started trading on Nasdaq on October 20, 2022. This offering aims to fund the development of Prime Editing technology, which has the potential to address a wide range of genetic diseases by correcting mutations.
Prime Medicine, Inc. (Nasdaq: PRME) has priced its upsized initial public offering of 10,294,118 shares at $17.00 each, aiming to raise approximately $175 million before expenses. The offering, managed by J.P. Morgan, Goldman Sachs, Morgan Stanley, and Jefferies, will commence trading on the Nasdaq Global Market on October 20, 2022, and is set to close on October 24, 2022. The company focuses on innovative genetic therapies using Prime Editing technology, which targets a wide range of genetic diseases.